FDA official says more control over drug warning labels would help

03/2/2005 | SeattlePI.com

An FDA official told a congressional hearing that information on serious drug side effects could more quickly reach the public if the agency had the authority to write the warning labels. Sandra Kweder, deputy director of the Office of New Drugs, told the hearing the agency currently must negotiate with drug companies over wording on warning labels, andna dispute between the agency and Merck over labeling for Vioxx once its health risks became known caused a delay in getting that information on the label. She said the power to require label changes "would be very helpful."

View Full Article in:

SeattlePI.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA